EXEL SP | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  21657 of 22110  at  3/13/2019 5:58:36 PM  by

JoeFlow


 In response to msg 21655 by  hbomb57108
view thread

Re: EXEL SP

 OS of "78.3% in the sunitinib group" say a lot about the relative health of these patients in 1L.  I think the bigger question is the size (n) of each trial.  KN426 had 863 patients scheduled into 2 arms.  CM-9ER has 630 patients in 3 arms.  Like I said, not at all surprising keytruda+VEGFR inhibitor blew away sunitinib.  Looks like the battle will be for OS and final OS may take a long time to hit with increased efficacy with these new regimens.
Does CM9ER even have an interim analysis scheduled?


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 275
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...